Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Infection-related arthritis
•
General Rheumatology
•
Infectious Disease
•
Infection Prevention and Control
In patients taking biologics who are planning joint replacement and are known MRSA carriers do you perform decolonization prior to surgery?
Related Questions
How often do you see bony erosions in patients with Lyme arthritis?
Is there a role for nitazoxanide for treatment of norovirus gastroenteritis in immunocompromised patients?
What specific criteria or patient conditions would make you hesitant to use fluoroquinolones early in the treatment course for managing MSSA joint infections with oral antibiotics?
Is there any role for administering another course of recombinant zoster vaccine (Shingrix) in a previously vaccinated patient with RA, who is in clinical remission on JAK inhibitor but has had a breakthrough shingles infection?
How would you treat an asymptomatic patient with a positive Blastomyces antibody, evidence of prior granulomatous lung disease on imaging, and who may require immunosuppression in the future?
How do you integrate next-generation sequencing with traditional culture methods to improve the identification of fungal pathogens, especially in cases where routine cultures are negative when evaluating suspected prosthetic joint infections?
Are there any concerns with live vaccine innoculation and patients who are on denosumab?
In light of recent measles outbreaks, have you adjusted your vaccination counseling or preventive strategies for adult immunocompromised patients?
How long do you recommend that a patient wear a mask when resuming biologic infusions following a recent upper respiratory infection?
Is there a risk of hepatitis C activation with rituximab in a patient who has a history of HCV treated with antivirals and who is in sustained viral response?
